799 results on '"Kimby, Eva"'
Search Results
2. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials
3. Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study
4. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
5. Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
6. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
7. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
8. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
9. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy
10. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas
11. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
12. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
13. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
14. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
15. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia
16. Response Assessment in Waldenström’s Macroglobulinaemia
17. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group
18. Figure S1-S8 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
19. Supplementary Tables S1-S2 from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
20. Data from TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
21. Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment
22. Supplementary Materials and Methods from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
23. Lack of reproducibility of histopathological features in MYC ‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
24. Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
25. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies
26. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
27. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
28. Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
29. Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
30. Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data
31. Career development:A balance of opportunities and choices
32. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
33. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
34. Nodal Marginal Zone Lymphoma
35. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
36. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
37. Survival by first-line treatment type and timing of progression among follicular lymphoma patients: A national population-based study in Sweden
38. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
39. Response Assessment in Waldenström’s Macroglobulinaemia
40. Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data.
41. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
42. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study
43. Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma
44. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
45. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse
46. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
47. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
48. TCL1A expression delineates biological and clinical variability in B-cell lymphoma
49. Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma
50. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.